Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nadia Bessoltane‐Bentahar"'
Autor:
Gaëlle Pierron, Nadège Corradini, Marion Gambart, Eve Lapouble, Valérie Combaret, Dominique Valteau-Couanet, Léo Colmet-Daage, Isabelle Janoueix-Lerosey, Mathieu Chicard, Jean Michon, Virginie Bernard, Adrien Danzon, Virginie Raynal, Gudrun Schleiermacher, Angela Bellini, Laura Le Roux, Olivier Delattre, Sylvain Baulande, Estelle Thebaud, Franck Bourdeaut, Jaydutt Bhalshankar, Caroline Louis-Brennetot, Julien Maslian Planchon, Anne-Sophie Defachelles, Nathalie Clément, Nadia Bessoltane‐Bentahar
Publikováno v:
International Journal of Cancer
In neuroblastoma (NB), genetic alterations in chromatin remodeling (CRGs) and epigenetic modifier genes (EMGs) have been described. We sought to determine their frequency and clinical impact. Whole exome (WES)/whole genome sequencing (WGS) data and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf9b3e1fe5107841695c12f9fdede13
http://europepmc.org/articles/PMC6771805
http://europepmc.org/articles/PMC6771805
Autor:
Jean Michon, Gudrun Schleiermacher, Malcolm A. Smith, JulieAnn Rader, Trevor J. Pugh, Patricia Legoix-Né, Jan Koster, Daniela S Gerhard, Edward F. Attiyeh, Olivier Delattre, Shahab Asgharzadeh, Julie M. Gastier-Foster, Sharon J. Diskin, Jan J. Molenaar, Leo Colmet Daage, Rogier Versteeg, Esther M. van Wezel, Eve Lapouble, Marli E. Ebus, Godelieve A.M. Tytgat, Javed Khan, Ellen M. Westerhout, Mathieu Chicard, Lori S. Hart, Nadia Bessoltane Bentahar, M. Emmy M. Dolman, Linda Schild, Anne Hakkert, Virginie Bernard, Valérie Combaret, Johannes H. Schulte, Angela Bellini, Jaime M. Guidry Auvil, Jun S. Wei, Thomas B.K. Watkins, Michael D. Hogarty, Shile Zhang, Thomas F. Eleveld, John M. Maris, Derek A. Oldridge, Huib N. Caron, Peter van Sluis, Isabelle Janoueix-Lerosey, Arlene Naranjo, C. Ellen van der Schoot, Danny A. Zwijnenburg
Publikováno v:
Nature genetics, 47(8), 864-871. Nature Publishing Group
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d15fdd102ad6e20dda578d08071396b
https://doi.org/10.1038/ng.3333
https://doi.org/10.1038/ng.3333
Autor:
Mathieu Chicard, Angela Bellini, Shile Zhang, Julie M. Gastier-Foster, Trevor J. Pugh, Valérie Combaret, Jean Michon, Gudrun Schleiermacher, Eve Lapouble, Edward F. Attiyeh, Huib N. Caron, Malcolm A. Smith, Marli E. Ebus, Godelieve A.M. Tytgat, Linda Schild, Rogier Versteeg, Jan J. Molenaar, Arlene Naranjo, M. Emmy M. Dolman, Olivier Delattre, Ellen M. Westerhout, Leo Colmet Daage, C. Ellen van der Schoot, Lori S. Hart, Nadia Bessoltane Bentahar, Jun Wei, Javed Khan, Thomas F. Eleveld, Anne Hakkert, Sharon J. Diskin, Danny A. Zwijnenburg, Virginie Bernard, Peter van Sluis, Thomas B.K. Watkins, Michael D. Hogarty, Johannes H. Schulte, JulieAnn Rader, Daniela S. Gerhard, Jan Koster, Esther M. van Wezel, Jaime M. Guidry Auvil, Isabelle Janoueix-Lerosey, Patricia Legoix-Né, John M. Maris, Derek A. Oldridge
Publikováno v:
Cancer Research. 75:2980-2980
Background The majority of high-risk neuroblastomas initially respond to chemotherapy, but over half of patients experience therapy-resistant relapses. The molecular defects driving relapse and drug resistance are unknown. Methods We performed Illumi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c334458b19f46e34fe3a60aee2bc74f9
https://doi.org/10.1158/1538-7445.am2015-2980
https://doi.org/10.1158/1538-7445.am2015-2980